Boston Area Diabetes Endocrinology Research Center Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2009
NCT00888628
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

Boston Area Diabetes Endocrinology Research Center (funded by NIDDK)

Active Ingredients

Drugs in Phase 2 Trials (2)

allogeneic pancreatic islet cells (1 trial)

etanercept (enbrel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 1 (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2